Jihye Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jihye Kim has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Jeong-Won Lee
Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
4 shared publications - Byoung-Gie Kim
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 shared publications - Chel Hun Choi
Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
2 shared publications - Duk-Soo Bae
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 shared publications Byoung-Gie Kim
Sungkyunkwan University School of Medicine, Samsung Medical Center, Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Seoul, Republic of Korea
1 shared publication- Chan Kyo Kim
Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- 6 December 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (5) , 102838
Survival implications of computed tomography–derived muscle mass changes in patients with epithelial ovarian cancer undergoing bowel surgery
- 6 December 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (5) , 102838
Survival implications of computed tomography–derived muscle mass changes in patients with epithelial ovarian cancer undergoing bowel surgery
- 27 June 2022
- Published by Wiley in International Journal of Cancer
- Vol. 151 (7) , 1086-1097
Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047)
Through the wide adaptation of next-generation sequencing (NGS) technology within clinical practice, molecular profiling of the tumor has been the principal component of personalized treatment. In our study, we have generated a large collection of cancer genomes on East Asian epithelial ovarian carcinoma (EOC) patients and demonstrate the feasibility and utility of NGS platforms to explore the dynamic interrelations of major cancer driver alterations and their impacts on clinical prognosis and management. A total of 652 EOC patients have undergone clinical NGS panels to determine the prevalence of germline and somatic mutations. Notably, TP53 was the most frequently altered event (73%), followed by both BRCA1 and BRCA2 (22% each) and MYC (19%) through pan-EOC analysis. When analyzed based on individual histopathological levels, TP53 mutation was highly dominant in high-grade serous and mucinous histology, whereas mutations in PIK3CA and ARID1A were mostly observed in clear cell carcinoma, and KRAS, BRAF, and CDKN2A mutations were enriched in endometrioid, low-grade serous, and mucinous tumors, respectively. The network-based probabilistic model showed significant co-occurrences of TP53 with BRCA1 and ALK with BRCA2, NOTCH1, and ROS1, whereas mutual exclusivity of TP53 with KRAS and PIK3CA was evident. Furthermore, we utilized machine-learning algorithms to identify molecular correlates that conferred increased sensitivity to platinum and olaparib treatments including somatic mutations in BRCA1, ATM, and MYC. Conversely, patients with ALK mutation were considerably resistant to both treatment modalities. Collectively, our results demonstrate the clinical feasibility of prospective genetic sequencing to facilitate personalized treatment opportunities for patients with EOC.
- 27 June 2022
- Published by Wiley in International Journal of Cancer
- Vol. 151 (7) , 1086-1097
Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047)
Through the wide adaptation of next-generation sequencing (NGS) technology within clinical practice, molecular profiling of the tumor has been the principal component of personalized treatment. In our study, we have generated a large collection of cancer genomes on East Asian epithelial ovarian carcinoma (EOC) patients and demonstrate the feasibility and utility of NGS platforms to explore the dynamic interrelations of major cancer driver alterations and their impacts on clinical prognosis and management. A total of 652 EOC patients have undergone clinical NGS panels to determine the prevalence of germline and somatic mutations. Notably, TP53 was the most frequently altered event (73%), followed by both BRCA1 and BRCA2 (22% each) and MYC (19%) through pan-EOC analysis. When analyzed based on individual histopathological levels, TP53 mutation was highly dominant in high-grade serous and mucinous histology, whereas mutations in PIK3CA and ARID1A were mostly observed in clear cell carcinoma, and KRAS, BRAF, and CDKN2A mutations were enriched in endometrioid, low-grade serous, and mucinous tumors, respectively. The network-based probabilistic model showed significant co-occurrences of TP53 with BRCA1 and ALK with BRCA2, NOTCH1, and ROS1, whereas mutual exclusivity of TP53 with KRAS and PIK3CA was evident. Furthermore, we utilized machine-learning algorithms to identify molecular correlates that conferred increased sensitivity to platinum and olaparib treatments including somatic mutations in BRCA1, ATM, and MYC. Conversely, patients with ALK mutation were considerably resistant to both treatment modalities. Collectively, our results demonstrate the clinical feasibility of prospective genetic sequencing to facilitate personalized treatment opportunities for patients with EOC.
- Open Access
- 1 February 2020
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 27 (2) , 473-481
In Vivo Comparison of MONOFIX, A Novel Barbed Suture with a Triangular Stopper, with Pre-existing Products in a Porcine Model
- 1 February 2020
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 27 (2) , 473-481
Open AccessIn Vivo Comparison of MONOFIX, A Novel Barbed Suture with a Triangular Stopper, with Pre-existing Products in a Porcine Model
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31 (2) , e15
Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study
Park SJ, et al. J Gynecol Oncol. 2019 Jun;31:e15. https://doi.org/10.3802/jgo.2020.31.e15
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31 (2) , e15
Open AccessReal world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study
Park SJ, et al. J Gynecol Oncol. 2019 Jun;31:e15. https://doi.org/10.3802/jgo.2020.31.e15
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (1) , e11
Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?
Kim J, et al. J Gynecol Oncol. 2018 Oct;30(1):e11. https://doi.org/10.3802/jgo.2019.30.e11
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (1) , e11
Open AccessOptimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?
Kim J, et al. J Gynecol Oncol. 2018 Oct;30(1):e11. https://doi.org/10.3802/jgo.2019.30.e11
- 1 January 2015
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 32 (1) , 13-16
Necrotizing enteritis with portal vein gas and pneumatosis cystoides intestinalis treated with delayed operation
Yoo JY, et al. Yeungnam Univ J Med. 2015 Jun;32(1):13-16. http://dx.doi.org/10.12701/yujm.2015.32.1.13
- 1 January 2015
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 32 (1) , 13-16
Necrotizing enteritis with portal vein gas and pneumatosis cystoides intestinalis treated with delayed operation
Yoo JY, et al. Yeungnam Univ J Med. 2015 Jun;32(1):13-16. http://dx.doi.org/10.12701/yujm.2015.32.1.13